Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Clinical trial NCT05132777 · UNKNOWN

Trial details

NCT number: NCT05132777
Sponsor: Shanghai JMT-Bio Inc.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced or Metastatic Non-Small Cell Lung Cancer EGFR Exon20 Insertion Mutations

Start date: 2021-11-20
Primary completion: 2023-09-30
Enrollment: 155

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.